PDS Biotechnology
PDSB
51 hedge funds and large institutions have $148M invested in PDS Biotechnology in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 23 increasing their positions, 8 reducing their positions, and 6 closing their positions.
188% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 8
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
7% more capital invested
Capital invested by funds: $139M → $148M (+$9.14M)
4% less funds holding
Funds holding: 53 → 51 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.02M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$1.71M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$1.01M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$854K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$539K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
-$1.37M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$568K |
| 3 |
Goldman Sachs
New York
|
-$453K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$233K |
| 5 |
Asset Management One
Tokyo,
Japan
|
-$229K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TCIM
51
TIAA CREF Investment Management
New York
| $471 | -$18.4K | -93 | -4% |
|
|
NC
52
Nexthera Capital
New York
| – | -$1.37M | -6,792 | Closed |
|
|
53
Goldman Sachs
New York
| – | -$453K | -2,239 | Closed |
|
|
RJA
54
Raymond James & Associates
St Petersburg,
Florida
| – | -$233K | -1,154 | Closed |
|
|
ARTA
55
A.R.T. Advisors
New York
| – | -$206K | -1,020 | Closed |
|
56
Citigroup
New York
| – | -$16K | -81 | Closed |
|
|
BJ
57
BlackRock Japan
Tokyo,
Japan
| – | -$8K | -38 | Closed |
|
PDSB Hedge Fund Activity: Q3 2016 in Review
51 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q3 2016, worth a combined $148M — up 6.6% from $139M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PDSB and 4 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 23 added.
The largest buyer was Vanguard Group, adding an estimated $2.02M. The largest seller was Nexthera Capital, exiting entirely with an estimated $1.37M sold.
- 51 institutional investors held PDS Biotechnology (PDSB) as of Q3 2016, down from 53 in Q2 2016.
- Funds reported $148M of PDS Biotechnology stock for Q3 2016, up 6.6% quarter-over-quarter.
- 4 funds opened new PDS Biotechnology positions in Q3 2016 and 6 closed out, a net change of -2 holders.
- The largest PDS Biotechnology buyer in Q3 2016 was Vanguard Group, an estimated $2.02M added.
- The largest PDS Biotechnology seller in Q3 2016 was Nexthera Capital, an estimated $1.37M sold.
Based on aggregated 13F filings for Q3 2016.